Mindbloom Opens A Psychedelic Treatment Location in New York City

Psychedelic medicine company Mindbloom has opened its first location in New York City. Located in the NoMad neighborhood of Manhattan, the company is offering. The company has plans to expand rapidly, with a new state-of-the-art flagship space set to open in the city later this year. Additional Mindbloom locations are planned for Los Angeles, San Diego, San Francisco, and Austin.

The treatment at this time offers physician-supervised ketamine treatments. Currently, when it comes to psychedelic medicines, MDMA and psilocybin treatments are still undergoing clinical trials for FDA approval. Ketamine is the only psychedelic medicine that can currently be prescribed in the U.S. The company said that at lower doses, ketamine can induce physical sensations and thought patterns described as psychedelic.

“Psychedelic medicine is increasingly demonstrating that it can provide profound, long-lasting and life-changing effects. We’re helping people achieve a deeper therapeutic experience in order to grow, heal and expand their human potential,” said Dylan Beynon, Mindbloom’s CEO. “We partner with licensed psychiatric clinicians to improve client outcomes by facilitating treatments in a comfortable, elevated, hospitality-inspired space.”

“Mindbloom’s therapy protocols are designed to alleviate suffering for depression or anxiety and facilitate lasting transformation for the people who need it most,” said Dr. Paleos, the company’s Medical Director. “Our programs are backed by extensive medical literature and my own experience researching psychedelic medicine for more than a decade and, more recently, providing ketamine therapy in my private practice.”

How It Works

Mindbloom’s initial offering is guided ketamine therapy, affordably priced at $150 – $250 per session. Prior to booking a session, patients undergo a rigorous initial screening which includes a psychiatric evaluation with a clinician, qualifying clients are prescribed a 4-session program of ketamine therapy administered via sublingual tablet or intramuscular injection. Each session lasts approximately one hour and takes place in a private, spa-like setting with amenities such as zero gravity chairs, weighted blankets, eye masks, noise-canceling headphones and aromatherapy on hand for optimal comfort. Afterward, clients reflect, refresh and journal on their experience in one of Mindbloom’s integration rooms.

Mindbloom has also developed a proprietary software platform to provide patients with customized psychedelic therapy programs and ongoing support throughout their therapeutic journey. In addition to video consultations, clients have access to remote treatment options such as 1:1 virtual integration therapy and coaching, designed to transform clients’ new insights into actionable plans for the day to day life.

The Founders

Paleos has devoted his career to researching ketamine and other psychedelic medicines such as MDMA and psilocybin in both academic and clinical settings. A Co-Principal Investigator for the NYU-Bellevue Ketamine for Depression Study, Dr. Paleos was one of the early researchers to identify ketamine as a breakthrough treatment for depression. Paleos is also a Principal Investigator and Study Therapist for the Multidisciplinary Association for Psychedelic Studies (MAPS)-sponsored MDMA-Assisted Psychotherapy for PTSD Phase 3 Clinical Trials. Previously, he was a Principal Investigator for the MDMA-Assisted Psychotherapy Phase 2 Clinical Trials and a Study Therapist for the NYU Psilocybin Cancer Anxiety Study.

Dylan Beynon is an impact entrepreneur with a track record of building socially conscious technology companies that have positively affected thousands of people across multiple markets. He is Co-founder and Chief Growth Officer at Mighty, a New York microfinance and civil justice company helping plaintiffs in need get a better deal from the justice system.

 

 

 

 

 

 

 

“At Mindbloom, we are democratizing access to psychedelic medicine and destigmatizing the most common, often crippling, mental health conditions,” said Beynon. “It’s our aim to become America’s trusted destination for cutting-edge, science-backed approaches to achieving and maintaining optimal wellness and mental health.”

Debra Borchardt

Debra BorchardtDebra Borchardt

Debra Borchardt is the CEO, Co-Founder, and Editor-In-Chief of GMR. She has covered the cannabis industry for several years at Forbes, Seeking Alpha and TheStreet. Prior to becoming a financial journalist, Debra was a Vice President at Bear Stearns where she held a Series 7 and Registered Investment Advisor license. Debra has a Masters degree in Business Journalism from New York University.


Leave a Reply

Your email address will not be published. Required fields are marked *

You may also like


About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


READ MORE



Recent Tweets

@GreenMarketRpt – 5 days

$SMG Scotts Miracle-Gro Increases Guidance As Hawthorne Sales Hit $300 Million

@GreenMarketRpt – 1 week

RT : Psychedelic-assisted therapy involves psychotherapeutic practices with a psychedelic as an adjunct. Research shows this has…

Back to Top

You have Successfully Subscribed!